2004
DOI: 10.1001/archotol.130.1.98
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Patients With Head and Neck Cancer Using Serum Protein Profiles

Abstract: Background: New and more consistent biomarkers of head and neck squamous cell carcinoma (HNSCC) are needed to improve early detection of disease and to monitor successful patient management.Objective: To determine if a new proteomic technology can correctly identify protein expression profiles for cancer in patient serum samples as well as detect the presence of a known tumor marker.Design: Direct proteomic analysis and comparison. Methods:The surface-enhanced laser desorption/ ionization time of flight mass s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
75
1
2

Year Published

2005
2005
2013
2013

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 102 publications
(78 citation statements)
references
References 35 publications
0
75
1
2
Order By: Relevance
“…The serum proteome would be expected to reflect what has been experienced or encountered by the blood during its constant perfusion through the body. SELDI-TOF MS has been demonstrated to be able to broadly explore the proteome and yield biomarkers that can be used individually or in combination to distinguish several forms of cancer from normal controls (12)(13)(14)(15). However, for exogenous exposures, the application of SELDI-TOF MS as a discovery tool to identify differentially expressed proteins has been limited.…”
mentioning
confidence: 99%
“…The serum proteome would be expected to reflect what has been experienced or encountered by the blood during its constant perfusion through the body. SELDI-TOF MS has been demonstrated to be able to broadly explore the proteome and yield biomarkers that can be used individually or in combination to distinguish several forms of cancer from normal controls (12)(13)(14)(15). However, for exogenous exposures, the application of SELDI-TOF MS as a discovery tool to identify differentially expressed proteins has been limited.…”
mentioning
confidence: 99%
“…[9][10][11][12][13][15][16][17][18][19][20][21]25 The most interesting discovery of the study was the finding that a SELDI-derived peak (m/z 4,462) was as effective at discriminating cancer from benign serum as the tumor markers CEA or CA19.9, while combining these three serum markers marginally improved classification. Classification could be further improved with data generated from a panel of peaks, suggesting analysis of proteomic profiles, rather than individual proteins, may yield improved diagnostic ability.…”
Section: Discussionmentioning
confidence: 99%
“…[9][10][11][12][13][15][16][17][18][19][20][21]25 A potential source of error in the tissue group not present in the serum study may be sampling error. The high desmoplastic nature of CCs means the sampled tissue may miss the malignant portion of the tumor and may mainly consist of stroma rather than cholangiocytes proper.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Despite significant investment in research to investigate different treatment regimens for HN cancer, limited improvement in patient survival has been achieved in the last 30 years in many countries [2]. One reason for this is that HN cancer is frequently diagnosed at an advanced stage.…”
Section: Introductionmentioning
confidence: 99%